@article {Frauchiger2002686，作者= {Frauchiger，贝蒂娜S.和Binggeli，塞韦林和Yammine，柔和斯派切尔，本和氪{\“U} GER，林恩和拉姆齐，凯瑟琳A.和Latzin，菲利普}，标题= {临床肺清除指数在儿童囊性纤维化}，elocation-ID = {2002686}，年= {} 2020，DOI = {10.1183 / 13993003.02686-2020}，出版商= {欧洲呼吸学会}，抽象= {理由的纵向课程188bet官网地址虽然肺清除指数（LCI）是小气道疾病的囊性纤维化（CF）的个体敏感标记物，较少有人知道在日常临床surveillance.Objectives在LCI纵向变化要在与CF描述儿童LCI的纵向过程临床常规监测和评估影响因素。方法与儿童年龄CF 3 {\ textendash}18年进行LCI测量每3个月作为常规临床护理的一部分，2011年和2018年之间，我们每次就诊记录的临床数据，我们使用了多层次的混合-effeCT模型，以确定随时间的变化LCI并识别临床因素影响LCI course.Measurements和主要结果我们收集LCI从1204次访问（3603个试验）在78名参与者，其中907次访问具有可接受的LCI数据。平均未经调整的增加LCI整个人口为0.29 LCI单元{\ textperiodcentered}年-1（95 \％CI 0.20 {\ textendash} 0.38）。在LCI的增加更为明显在青春期，用0.41单位{\ textperiodcentered}年-1（95 \％CI 0.27 {\ textendash} 0.54）。无论使用哪种绿脓杆菌或烟曲霉，肺部症状加重，CF相关糖尿病和支气管肺曲霉定植用在LCI随着时间的推移增幅较高有关。在调整了临床危险因素减少了LCI随时间0.24 LCI单元{\ textperiodcentered}年-1的增加（95 \％CI 0.16 {\ textendash} 0.33）。结论LCI常规临床监测期间测量与在基础疾病进展相关儿童CF. An increased change in LCI over time should prompt further diagnostic intervention.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Frauchiger has nothing to disclose.Conflict of interest: Dr. Binggeli has nothing to disclose.Conflict of interest: Dr. Yammine reports grants from Swiss National Science Foundation, outside the submitted work.Conflict of interest: Dr. Spycher reports grants from Swiss National Science Foundation, grants from Swiss Cancer League, outside the submitted work.Conflict of interest: Dr. Kr{\"u}ger has nothing to disclose.Conflict of interest: Dr. Ramsey reports grants from Swiss National Science Foundation, outside the submitted work.Conflict of interest: Dr. Latzin reports grants from Vertex, during the conduct of the study; personal fees from Vertex, personal fees from Novartis, personal fees from Roche, personal fees from Polyphor, personal fees from Vifor, personal fees from Gilead, personal fees from Schwabe, personal fees from Zambon, personal fees from Santhera, grants from Vertex, outside the submitted work.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2020/12/10/13993003.02686-2020}, eprint = {//www.qdcxjkg.com/content/early/2020/12/10/13993003.02686-2020.full.pdf}, journal = {European Respiratory Journal} }